CEACAM5 and exocrine pancreatic carcinoma: Included in these studies are colorectal, breast, esophageal, stomach, lung, gastric, and pancreatic carcinomas as well as CEA-positive tumors regardless of their sites of origin (www.clinicaltrials.gov).